The University Institute of Pharmaceutical Sciences of the Panjab University is a premier institution of Pharmaceutical Education and Research in the country. The institute has covered a long and glorious journey of 76 years starting from Lahore in 1944 and finally settling to the present campus in Chandigarh at the foothills of Himachal. In its travelogue, the institute crossed multiple milestones and continue to head ahead towards the well-defined goals. The elevation of the status from department to the level of an institute i.e. University Institute of Pharmaceutical Sciences in 1994, and hosting of Indian Pharmaceutical Congress in the same year, two presidential honors of the Indian Pharmaceutical Congresses to its faculty members, a special recognition by the UGC by granting SAP in 1993 and COSIST in 1981 establishment of ICMR Advanced Centre for standardization of Drugs of Indian System of Medicine are some of the major hallmarks on the path treaded so far.
Roche announced that the U.S. Food and Drug Administration (FDA) granted accelerated approval to Tecentriq® (atezolizumab) for the treatment of people with locally advanced or metastatic urothelial carcinoma (mUC) who have disease progression during or following platinum-based chemotherapy, or whose disease has worsened within 12 months of receiving platinum-based chemotherapy before surgery (neoadjuvant) or after surgery (adjuvant). Urothelial carcinoma accounts for 90% of all bladder cancers and can also be found in the renal pelvis, ureter and urethra.
